Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases
暂无分享,去创建一个
J. Seidelin | P. Munkholm | A. Popa | F. Bendtsen | J. Kjeldsen | J. Burisch | M. D. Jensen | C. Aalykke | N. Pedersen | K. Haderslev | S. Wildt | H. Jacobsen | W. Cebula | M. Attauabi | J. Fassov | A. Neumann | T. Knudsen | Cecilie Lind | A. Molazahi | C. Höglund | Kenneth Bo Pedersen | H. B. Hansen